| 1 | Psychiatr Rehabil J 2003 -1 27: 59-68 |
|---|---|
| PMID | 12967233 |
| Title | 患有精神分裂症的年轻人的工作场所住宿和保护：一项混合方法研究。 |
| 抽象的 | Employment is an important outcome for individuals with精神分裂症and the Americans with Disabilities Act (艾达）是一个关键的结构变量，旨在有利地影响工作。关于个人如何理解和利用的知之甚少艾达rights. The purpose of this mixed method study was to elicit understanding of the knowledge and use of艾达来自20人的规定精神分裂症who returned to work. Three distinct groups emerged. Group differences suggest that use of艾达食品可能取决于个人需求和舒适艾达opportunity. |
| SCZ Keywords | 精神分裂症，精神分裂症 |
| 2 | 是。J. Med。2005年4月118日补充2：15S-22S |
| PMID | 15903291 |
| Title | Metabolic issues and cardiovascular disease in patients with psychiatric disorders. |
| 抽象的 | Individuals with psychiatric disorders tend to have excessive morbidity. They typically have high rates of respiratory illnesses, infectious diseases, substance abuse (including smoking), obesity, diabetes mellitus, and cardiovascular disease (CVD). Persons with精神分裂症情感障碍还具有CVD的危险因素的高流行率，例如糖尿病和肥胖症，其处于比一般人群高的1.5至2.0倍的阶；这转化为CVD引起的死亡率提高。某些心理学的使用会导致代谢后遗症，例如肥胖，血脂异常，葡萄糖失调和代谢综合征。这些后遗症加剧了这一人中CVD和糖尿病的风险升高。因此，使用的精神剂的使用导致体重增加过多，不仅增加了治疗患者患者的医生的另一个并发症精神分裂症but also may have serious prognostic and cost implications with respect to treatment-related diabetes and coronary disease incidence. The recent American Diabetes Association (艾达) Consensus Panel concluded that some agents are associated with greater diabetes risk than others. The current review describes the prevalence of the metabolic syndrome in people with affective disorders and精神分裂症populations, its prognostic relevance, and its exacerbation among patients treated with particular psychotropic agents, including certain atypical antipsychotics, selective serotonin reuptake inhibitors, and mood stabilizers. The costs associated with the treatment of the metabolic syndrome, diabetes, and coronary heart disease in populations with精神分裂症are also described. |
| SCZ Keywords | 精神分裂症，精神分裂症 |
| 3 | 是。J. Med。2005年4月118日补充2：15S-22S |
| PMID | 15903291 |
| Title | Metabolic issues and cardiovascular disease in patients with psychiatric disorders. |
| 抽象的 | Individuals with psychiatric disorders tend to have excessive morbidity. They typically have high rates of respiratory illnesses, infectious diseases, substance abuse (including smoking), obesity, diabetes mellitus, and cardiovascular disease (CVD). Persons with精神分裂症情感障碍还具有CVD的危险因素的高流行率，例如糖尿病和肥胖症，其处于比一般人群高的1.5至2.0倍的阶；这转化为CVD引起的死亡率提高。某些心理学的使用会导致代谢后遗症，例如肥胖，血脂异常，葡萄糖失调和代谢综合征。这些后遗症加剧了这一人中CVD和糖尿病的风险升高。因此，使用的精神剂的使用导致体重增加过多，不仅增加了治疗患者患者的医生的另一个并发症精神分裂症but also may have serious prognostic and cost implications with respect to treatment-related diabetes and coronary disease incidence. The recent American Diabetes Association (艾达) Consensus Panel concluded that some agents are associated with greater diabetes risk than others. The current review describes the prevalence of the metabolic syndrome in people with affective disorders and精神分裂症populations, its prognostic relevance, and its exacerbation among patients treated with particular psychotropic agents, including certain atypical antipsychotics, selective serotonin reuptake inhibitors, and mood stabilizers. The costs associated with the treatment of the metabolic syndrome, diabetes, and coronary heart disease in populations with精神分裂症are also described. |
| SCZ Keywords | 精神分裂症，精神分裂症 |
| 4 | Curr Drug Saf 2006 8月1日：227-41 |
| PMID | 18690933 |
| Title | The role of atypical antipsychotic agents in the treatment of schizophrenia and schizoaffective disorders in the elderly. |
| 抽象的 | 精神分裂症and schizoaffective disorder are prevalent in 1% of the adult population. The condition was thought to predominantly affect the young however recent studies have shown that the condition occurs in individuals throughout the life-span. The aim of this review is to discuss the role of atypical antipsychotics in treating schizoaffective disorder and精神分裂症在老年人中。The advent of atypical antipsychotics has made significant strides in the pharmacotherapy of精神分裂症在老年人中。他们是一样有效的conventional agents in reducing the positive symptoms, possibly some what more efficacious in reducing negative symptoms and appear to have a relatively safer adverse effect profile. However metabolic side affects particularly glucose abnormalities and weight gain, cerebrovascular effects, and mortality risk noted in dementia patients are gaining increasing attention. Appropriate monitoring for the metabolic side effects has been recommended by agencies such as the FDA (United States Food and Drug Administration),艾达（美国糖尿病协会）和APA（美国精神病协会）。与年龄相关的生物学因素，对药物反应和合并症的存在和伴随药物的存在的治疗使老年患者的治疗变得复杂。当前的研究支持非beplay苹果手机能用吗典型抗精神病药在治疗中的作用精神分裂症和老年人的精神分裂症。尽管与常规药物相比有优势，但即使使用这些耐受性更好的药物，仍然对成功治疗的挑战仍然存在。 |
| SCZ Keywords | 精神分裂症，精神分裂症 |
| 5 | J Clin Psychiatry 2006 Oct 67: 1493-500 |
| PMID | 17107239 |
| Title | Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evaluation of incidence and screening methods. |
| 抽象的 | 评估2种不同筛查指南的诊断特性，以检测被诊断为患者的患者精神分裂症。 在2年的时间内（2003年11月至2005年11月），415例患者精神分裂症用完整的实验室筛查和75克口服葡萄糖耐受性测试（OGTT）进行筛查。将两种筛选策略的灵敏度与“黄金标准”进行了比较：OGTT。正如美国精神病学协会/美国糖尿病协会（APA/艾达),(2)筛选策略源自于guidelines of the World Health Organization of assessing fasting glucose in all patients (step 1) and subsequently performing an OGTT in patients with impaired fasting glucose (step 2). Of the total sample, 6.3% (N = 26) met criteria for diabetes, resulting in a mean annual incidence of diabetes of 3.15% (6.3% incident cases/2 years). A screening based on the APA/艾达在OGTT确定的26例病例中，有12例（46.2％）检测到糖尿病的指南。提出的2步策略检测到26例26例中的25个（96.2％）。 The data suggest a high incidence of diabetes in patients diagnosed with精神分裂症。However, the guidelines to detect diabetes as proposed by the APA/艾达did not sufficiently detect diabetes in this specific high-risk group. The alternative 2-step strategy was able to detect the vast majority of diabetes cases and should therefore be considered in the clinical routine of screening and monitoring patients with精神分裂症。 |
| SCZ Keywords | 精神分裂症，精神分裂症 |
| 6 | Fortschr Neurol Psychiatr 2008 12月76日：703-14 |
| PMID | 18924059 |
| Title | [通过非典型抗精神病药治疗的精神分裂症患者体重管理的治疗选择]。 |
| 抽象的 | 最近几年（直到2007年12月）对2500篇文章的广泛，选择性文献综述，主要是从Medline和Cochrane出发的，用作搜索词“抗精神病药或精神分裂症or individual drug names (amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, ziprasidone)" and the terms "BMI, weight gain, metabolic syndrome, diabetes, lipid(s), cholesterol, triglycerides" was conducted. Regardless of the advantages ascribed to atypical antipsychotics and the special effectiveness of clozapine in patients resistant to therapy and at risk for suicide, the probability of weight gain is considerably increased for some of these substances. Patients with精神分裂症have a considerably reduced life expectancy associated with an increased prevalence of cardiovascular risk factors. There is a lack of practical guidelines integrated into clinical psychiatric care for the management of cardiovascular risk factors. The monitoring of patients treated with atypics, which has been recommended in the APA/艾达鉴于这些事实，共识论文在临床实践中的确定不足。定期监测可以向患者传达自我控制和动力。在相应的风险星座的情况下，必须考虑有关适应症和治疗的进一步决定。特别是强烈建议使用高心血管风险概况的患者参加预防目的的体重管理计划。这样的特殊计划应包括饮食治疗和行为和运动疗法的要素。首先对照研究表明，在应用这种结构化程序时，有效预防体重增加和代谢变化。此处提出的以实践为导向的逐步概念旨在为实施所需的医学和心理教育措施的实施，从精神分裂症。 |
| SCZ Keywords | 精神分裂症，精神分裂症 |
| 7 | Fortschr Neurol Psychiatr 2008 12月76日：703-14 |
| PMID | 18924059 |
| Title | [通过非典型抗精神病药治疗的精神分裂症患者体重管理的治疗选择]。 |
| 抽象的 | 最近几年（直到2007年12月）对2500篇文章的广泛，选择性文献综述，主要是从Medline和Cochrane出发的，用作搜索词“抗精神病药或精神分裂症or individual drug names (amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, ziprasidone)" and the terms "BMI, weight gain, metabolic syndrome, diabetes, lipid(s), cholesterol, triglycerides" was conducted. Regardless of the advantages ascribed to atypical antipsychotics and the special effectiveness of clozapine in patients resistant to therapy and at risk for suicide, the probability of weight gain is considerably increased for some of these substances. Patients with精神分裂症have a considerably reduced life expectancy associated with an increased prevalence of cardiovascular risk factors. There is a lack of practical guidelines integrated into clinical psychiatric care for the management of cardiovascular risk factors. The monitoring of patients treated with atypics, which has been recommended in the APA/艾达鉴于这些事实，共识论文在临床实践中的确定不足。定期监测可以向患者传达自我控制和动力。在相应的风险星座的情况下，必须考虑有关适应症和治疗的进一步决定。特别是强烈建议使用高心血管风险概况的患者参加预防目的的体重管理计划。这样的特殊计划应包括饮食治疗和行为和运动疗法的要素。首先对照研究表明，在应用这种结构化程序时，有效预防体重增加和代谢变化。此处提出的以实践为导向的逐步概念旨在为实施所需的医学和心理教育措施的实施，从精神分裂症。 |
| SCZ Keywords | 精神分裂症，精神分裂症 |
| 8 | Encephale 2009 Sep 35: 330-9 |
| PMID | 19748369 |
| Title | [Drawing up guidelines for the attendance of physical health of patients with severe mental illness]. |
| 抽象的 | Having a mental illness has been and remains even now, a strong barrier to effective medical care. Most mental illness, such as精神分裂症，躁郁症和抑郁症与医疗发病率和死亡率不当有关。它代表了一个重大的健康问题，与普通人群相比，寿命短15至30年。 基于这些事实，由专家小组召集了一个研讨会：精神科医生，内分泌学家，心脏病学家，内科医生和药理学家，来自一些法国医院，以审查患有严重精神疾病患者的合并症和死亡率有关的信息治疗代谢性疾病的发展和最后的心血管疾病。法国专家就这些观点强烈同意：患有严重精神疾病的患者具有更高的可预防危险因素，例如吸烟，成瘾，饮食不良，缺乏运动；与患者有关的障碍，疾病，医生的态度以及医疗保健服务的结构，使发病率的认可和管理更加困难；并改善患有严重精神疾病患者合并症医学疾病的检测和治疗将对他们的社会心理功能和整体生活质量带来重大好处。启动抗精神病药疗法的指南：基于这些因素，法国专家在启动和维持抗精神病药物化合物时提出了实践精神科医生的指南。该准则的目的是实用，并涉及精神疾病的第一集，与其他专家，家庭从业人员的合并症的管理以及一些关键点的后续行动有关医学疾病的发现。该准则分为两个主要部分。第一部分提供了：严重精神疾病患者的死亡率和合并症的综述：发病率和死亡率的增加主要是由于心血管疾病过早（心肌梗塞，中风...）。心血管事件与无修改的风险密切相关。年龄，性别，个人和/或家族史等因素，以及至关重要的改变危险因素，例如超重和肥胖，血脂异常，糖尿病，高血压和吸烟。 Although these classical risk factors exist in the general population, epidemiological studies suggest that patients with severe mental illness have an increased prevalence of these risk factors. The causes of increased metabolic and cardiovascular risk in this population are strongly related to poverty and limited access to medical care, but also to the use of psychotropic medication. A review of major published consensus guidelines for metabolic monitoring of patients treated with antipsychotic medication that have recommended stringent monitoring of metabolic status and cardiovascular risk factors in psychiatric patients receiving antipsychotic drugs. There have been six attempts, all published between 2004 and 2005: Mount Sinai, Australia,艾达-apa，比利时，英国，可以艾达。每个指南都有特定的,有点不和谐, recommendations about which patients and drugs should be monitored. However, there was agreement on the importance of baseline monitoring and follow-up for the first three to four months of treatment, with subsequent ongoing reevaluation. There was agreement on the utility of the following tests and measures: weight and height, waist circumference, blood pressure, fasting plasma glucose, fasting lipid profile. In the second part, the French experts propose guidelines for practising psychiatrists when initiating and maintaining therapy with antipsychotic drugs: the first goal is identification of risk factors for development of metabolic and cardiovascular disorders: non modifiable risk factors: these include: increasing age, gender (increased rates of obesity, diabetes and metabolic syndrome are observed in female patients treated with antipsychotic drugs), personal and family history of obesity, diabetes, heart disease, ethnicity as we know that there are increased rates of diabetes, metabolic syndrome and coronary heart disease in patients of non European ethnicity, especially among South Asian, Hispanic, and Native American people. Modifiable risk factors: these include: obesity, visceral obesity, smoking, physical inactivity, and bad diet habits. Then the expert's panel focussed on all the components of the initial visit such as: family and medical history; baseline weight and BMI should be measured for all patients. Body mass index can be calculated by dividing weight (in kilograms) by height (in meters) squared; visceral obesity measured by waist circumference; blood pressure; fasting plasma glucose; fasting lipid profiles. These are the basic measures and laboratory examinations to do when initiating an antipsychotic treatment. ECG: several of the antipsychotic medications, typical and atypical, have been shown to prolong the QTc interval on the ECG. Prolongation of the QTc interval is of potential concern since the patient may be at risk for wave burst arrhythmia, a potentially serious ventricular arrhythmia. A QTc interval greater than 500 ms places the patient at a significantly increased risk for serious arrhythmia. QTc prolongation has been reported with varying incidence and degrees of severity. The atypical antipsychotics can also cause other cardiovascular adverse effects with, for example, orthostatic hypotension. Risk factors for cardiovascular adverse effects with antipsychotics include: known cardiovascular disease, electrolyte disorders, such as hypokaliemia, hypomagnesaemia, genetic characteristics, increasing age, female gender, autonomic dysfunction, high doses of antipsychotics, the use of interacting drugs, and psychiatric illness itself. In any patient with pre-existing cardiac disease, a pre-treatment ECG with routine follow-up is recommended. 抗精神病药的患者应定期对血糖，脂质剖面以及体重，腰围和血压进行定期测试，并在措施之间进行建议的时间间隔。临床医生应跟踪治疗对物理和生物学参数的影响，并应促进获得适当的医疗服务。为了防止或限制可能的副作用，必须向患者及其家人提供有关心血管和代谢风险的信息。实施这些建议的成本效益是相当大的：实验室测试的成本和额外的设备成本（例如尺度，磁带测量和血压设备）是适度的。监测代谢异常的责任问题是辩论的。然而，抗精神病药的处方涉及监测潜在的药物诱导的代谢异常的责任。代谢疾病的发作将暗示特定的治疗方法。精神科医生，全科医生，内分泌学家，心脏病学家，护士，营养师和家庭的协调行动无疑是确保这些患者最佳护理的关键决定因素。 |
| SCZ Keywords | 精神分裂症，精神分裂症 |
| 9 | Rev Bras Psiquiatr 2010 Sep 32: 275-8 |
| PMID | 20414589 |
| Title | Lower frequency of the low activity adenosine deaminase allelic variant (ADA1*2) in schizophrenic patients. |
| 抽象的 | 腺苷可能在病理生理中起作用精神分裂症，由于它调节了几种神经递质的释放，例如谷氨酸，多巴胺，5-羟色胺和乙酰胆碱，可通过POS突触超极化降低神经元活性，并抑制多巴胺能活性。腺苷脱氨酶通过将腺苷转化为肌苷参与嘌呤代谢。腺苷脱氨酶（22G？a）的最常见功能多态性（艾达1*2) exhibits 20-30% lower enzymatic activity in individuals with the G/A genotype than individuals with the G/G genotype. The aim of this study was to evaluate the艾达多态性22G？a（艾达1*2）在精神分裂症patients and healthy controls. 的基因型艾达22G？a在152中具有等位基因特异性PCR策略的标识精神分裂症患者和111个健康个体。 A significant decrease in the frequency of the G/A genotype was seen in精神分裂症patients (7/152 - 4.6%) relative to controls (13/111 - 11.7%, p = 0.032, OR = 2.6). 这些结果表明，与低腺苷脱氨酶活性相关的G/A基因型，并且在促进的腺苷水平较高的情况下，在精神分裂症患者。 |
| SCZ Keywords | 精神分裂症，精神分裂症 |
| 10 | Rev Bras Psiquiatr 2010 Sep 32: 275-8 |
| PMID | 20414589 |
| Title | Lower frequency of the low activity adenosine deaminase allelic variant (ADA1*2) in schizophrenic patients. |
| 抽象的 | 腺苷可能在病理生理中起作用精神分裂症，由于它调节了几种神经递质的释放，例如谷氨酸，多巴胺，5-羟色胺和乙酰胆碱，可通过POS突触超极化降低神经元活性，并抑制多巴胺能活性。腺苷脱氨酶通过将腺苷转化为肌苷参与嘌呤代谢。腺苷脱氨酶（22G？a）的最常见功能多态性（艾达1*2) exhibits 20-30% lower enzymatic activity in individuals with the G/A genotype than individuals with the G/G genotype. The aim of this study was to evaluate the艾达多态性22G？a（艾达1*2）在精神分裂症patients and healthy controls. 的基因型艾达22G？a在152中具有等位基因特异性PCR策略的标识精神分裂症患者和111个健康个体。 A significant decrease in the frequency of the G/A genotype was seen in精神分裂症patients (7/152 - 4.6%) relative to controls (13/111 - 11.7%, p = 0.032, OR = 2.6). 这些结果表明，与低腺苷脱氨酶活性相关的G/A基因型，并且在促进的腺苷水平较高的情况下，在精神分裂症患者。 |
| SCZ Keywords | 精神分裂症，精神分裂症 |
| 11 | Int J风险SEX MED 2011 -1 23：181-5 |
| PMID | 22020398 |
| Title | Obesity, diabetes and hypertension associated with antipsychotic use in remitted schizophrenia. |
| 抽象的 | To ascertain the prevalence of diabetes, obesity and hypertension associated with antipsychotic use in remitted patients with精神分裂症。 This study included a cross sectional survey of diabetes, obesity and hypertension among all remitted patients diagnosed with精神分裂症至少6个月的抗精神病药物治疗中的精神分裂症（n = 130）。 A prevalence of 35.4% obesity, 1.5% hypertension and 3.8% (艾达) or 5.4% (WHO) prevalence of diabetes was observed. The use of antipsychotic drugs in the long run may be associated with a significantly greater risk of developing obesity with moderate influence on development of diabetes and minimal to none on hypertension. |
| SCZ Keywords | 精神分裂症，精神分裂症 |
| 12 | Hum Psychopharmacol 2011 3月26日：120-4 |
| PMID | 21412846 |
| Title | 腺苷能活性与氯氮平在慢性精神分裂症治疗的效力上的相关性：一项双盲随机试验。 |
| 抽象的 | 有人提出，腺苷能活性的不足可能有助于精神分裂症。作者进行了这项研究，以进一步评估腺苷脱氨酶的水平（艾达）慢性患者精神分裂症treated with monotherapy of haloperidol, risperidone or clozapine and correlation between the艾达level with response to treatment. 该试验是对平行于慢性患者平行组的前瞻性，为期8周的双盲研究精神分裂症。该研究的合格参与者是51例慢性患者精神分裂症with ages ranging from 20 to 45 years. All participants were inpatients, in the active phase of illness, and met DSM-IV-TR criteria for精神分裂症。将患者随机分配（每组17例）为利培酮（6 mg/day）或氟哌啶醇15 mg/天或氯氮平（300 mg/day）。血清艾达在基线和第8周测量活动。 血浆水平艾达慢性患者精神分裂症接受氯氮平的人明显高于接受氟哌啶醇的患者。此外，对治疗的反应与血浆水平呈正相关艾达仅在氯氮平组（r？=？0.46和p？=？0.04）中。 结果表明酶的活性增加艾达in the serum of精神分裂症接受氯氮平治疗的患者，这种增加可能与氯氮平的优质抗精神病药物相关。 |
| SCZ Keywords | 精神分裂症，精神分裂症 |
| 13 | Hum Psychopharmacol 2011 3月26日：120-4 |
| PMID | 21412846 |
| Title | 腺苷能活性与氯氮平在慢性精神分裂症治疗的效力上的相关性：一项双盲随机试验。 |
| 抽象的 | 有人提出，腺苷能活性的不足可能有助于精神分裂症。作者进行了这项研究，以进一步评估腺苷脱氨酶的水平（艾达）慢性患者精神分裂症treated with monotherapy of haloperidol, risperidone or clozapine and correlation between the艾达level with response to treatment. 该试验是对平行于慢性患者平行组的前瞻性，为期8周的双盲研究精神分裂症。该研究的合格参与者是51例慢性患者精神分裂症with ages ranging from 20 to 45 years. All participants were inpatients, in the active phase of illness, and met DSM-IV-TR criteria for精神分裂症。将患者随机分配（每组17例）为利培酮（6 mg/day）或氟哌啶醇15 mg/天或氯氮平（300 mg/day）。血清艾达在基线和第8周测量活动。 血浆水平艾达慢性患者精神分裂症接受氯氮平的人明显高于接受氟哌啶醇的患者。此外，对治疗的反应与血浆水平呈正相关艾达仅在氯氮平组（r？=？0.46和p？=？0.04）中。 结果表明酶的活性增加艾达in the serum of精神分裂症接受氯氮平治疗的患者，这种增加可能与氯氮平的优质抗精神病药物相关。 |
| SCZ Keywords | 精神分裂症，精神分裂症 |
| 14 | Fish Physiol. Biochem. 2015 Dec 41: 1383-92 |
| PMID | 26156500 |
| Title | Investigation into effects of antipsychotics on ectonucleotidase and adenosine deaminase in zebrafish brain. |
| 抽象的 | 抗精神病药用于治疗多种脑疾病患者的精神病症状，例如精神分裂症。非典型和典型的抗精神病药在其临床和副作用方面有所不同。氟哌啶醇是一种代表性的典型抗精神病药，具有有效的多巴胺受体拮抗功能。然而，已经开发了非典型抗精神病药，并表征了在治疗中的重要进步精神分裂症and other psychotic disorders. Purine nucleotides and nucleosides, such as ATP and adenosine, constitute a ubiquitous class of extracellular signaling molecules crucial for normal functioning of the nervous system. Indirect findings suggest that changes in the purinergic system, more specifically in adenosinergic activity, could be involved in the pathophysiology of精神分裂症。We investigated the effects of typical and atypical antipsychotics on ectonucleotidase and adenosine deaminase (艾达) activities, followed by an analysis of gene expression patterns in zebrafish brain. Haloperidol treatment (9 �M) was able to decrease ATP hydrolysis (35%), whereas there were no changes in hydrolysis of ADP and AMP in brain membranes after antipsychotic exposure. Adenosine deamination in membrane fractions was inhibited (38%) after haloperidol treatment when compared to the control; however, no changes were observed in艾达氟哌啶醇暴露后的可溶性级分。硫磺（250°M）和奥氮平（100 |）没有改变核苷酸酶和艾达activities. Haloperidol also led to a decrease in entpd2_mq, entpd3 and艾达l mRNA transcripts. These findings demonstrate that haloperidol is an inhibitor of NTPDase and艾达activities in zebrafish brain, suggesting that purinergic signaling may also be a target of pharmacological effects promoted by this drug. |
| SCZ Keywords | 精神分裂症，精神分裂症 |
| 15 | Redox Rep. 2015 Jul 20: 170-6 |
| PMID | 25545018 |
| Title | Paliperidone regulates intracellular redox system in rat brain: Role of purine mechanism. |
| 抽象的 | The treatment of精神分裂症是多因素的，抗精神病药物包括治疗的主要部分。Paliperidone是一种新的商业化抗精神病药，其配方包括主要的活性代谢物利培酮，9-羟基糖尿病。自从之间的关系精神分裂症首先证明了氧化应激，已经进行了许多研究，以探测抗精神病药对氧化剂抗氧化剂系统和脂质过氧化的潜在保护作用。这项研究的基本目的是确定新销售的药帕吡啶酮对酶腺苷脱氨酶活性的影响（艾达），黄嘌呤氧化酶（XO），超氧化物歧化酶（SOD），过氧化氢酶（CAT）和谷胱甘肽过氧化物酶（GSH-PX）以及大鼠脑组织中的丙二醛（MDA）和一氧化氮（NO）水平。 该研究使用了二十只雄性Sprague-Dawley大鼠，分为两组。第一个是对照组（n = 10），第二个是棕榈酮组（n = 10）。盐水每天在对照组中每天服用一次14天。在棕榈酮组中，每天以1 mg/kg的剂量服用帕利吡啶酮14天。所有大鼠在第十四天结束时均被牺牲。收集大脑样品，然后分析。 我们的结果表明，棕榈酮显着降低了艾达(P = 0.015), XO (P = 0.0001), and CAT (P = 0.004) while insignificantly increasing the activity of SOD (P = 0.49), MDA (P = 0.71), and NO (P = 0.26) levels in rat brain tissues. In addition, paliperidone insignificantly decreased the activity of GSH-Px (P = 0.30) compared to the control group in rat brain tissues. 总之，这项研究中获得的数据表明，棕榈酮可以积极改变抗氧化剂状态，因此可以在治疗中提供积极的结果精神分裂症通过减少酶的活性艾达and XO, which are associated with purine metabolism. We believe that such a comprehensive approach used with other antipsychotic drugs warrants further study. |
| SCZ Keywords | 精神分裂症，精神分裂症 |